ArticleTransplantation direct2025
Optimal Utilization of Donors Aged ≥65 Y in Lung Transplantation to Increase Donor Availability While Maintaining Comparable Posttransplant Outcomes.
Article in Transplantation direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Utilizing older donors (≥65 y) in lung transplantation can greatly expand donor availability while potentially maintaining typical survival outcomes in certain subpopulations, such as older recipients, especially compared to survival with single lung transplants (which comprise ~20%-25% of US lung transplants according to recent data). Methods: This study included US adult lung transplants from 2010 to 2021 in the Scientific Registry for Transplant Recipients. To compare patient groups defined by donor age (D < 65 or D ≥ 65) and transplant type (single or double), stratified by recipient age (R18-39, R40-64, R ≥ 65), Inverse probability of treatment weighting was used to generate Kaplan-Meier survival estimates adjusted for >15 available covariates. Results: In R40-64, survival with D ≥ 65 double (adjusted median survival [aMS] = 7.1 [3.3-12.0] y, n = 150, Conclusions: Among lung recipients aged 40-64 y, donor age ≥65 y double transplants yield survival at least matching that of donor age <65 y single transplants. Among recipients aged ≥65 y, donor age ≥65 y double or single transplants yield survival comparable to that of donor age <65 single transplants. Compared with donor age <65 y double transplants, donor age ≥65 y double transplants had only ≤10 mo shorter adjusted median survival, within recipients aged ≥40 y. Judiciously increasing utilization of donors aged ≥65 y within recipients aged ≥40 y can reduce deaths among patients needing a lung transplant by decreasing donor scarcity, while maintaining favorable posttransplant survival.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.